FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | |||
|
||||
Senior Member
|
Apparently MBP8298, now called Dirucotide, is being scraped. I volunteered for this clinical trial and was turned down. I was hoping it would be another MS treatment. All trials on this will be scapped for now.
http://www.reuters.com/article/rbssP...54890120090727 BioMS Medical Corp Investor Relations said: Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial In Secondary Progressive Multiple Sclerosis. INDIANAPOLIS, Indiana and EDMONTON, Alberta, July 27, 2009 – Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study.
__________________
LADY May happiness be at your door. May it knock early, stay late, and leave the gift of good health behind. "Life is what it is". We can only focus on controlling those things we can control, we must let go of the things we can't. |
|||
![]() |
![]() |
|
|